KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Non-Current Assets (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Non-Current Assets data on record, last reported at -$16.5 billion in Q1 2025.

  • For Q1 2025, Non-Current Assets rose 4.28% year-over-year to -$16.5 billion; the TTM value through Mar 2025 reached -$74.6 billion, down 9.66%, while the annual FY2025 figure was -$16.6 billion, 6.71% up from the prior year.
  • Non-Current Assets reached -$16.5 billion in Q1 2025 per TAK's latest filing, up from -$17.3 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $96.4 billion in Q1 2021 and bottomed at -$18.1 billion in Q1 2023.
  • Average Non-Current Assets over 5 years is $27.1 billion, with a median of -$16.5 billion recorded in 2025.
  • Peak YoY movement for Non-Current Assets: skyrocketed 524.86% in 2021, then plummeted 119.9% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $96.4 billion in 2021, then dropped by 5.48% to $91.1 billion in 2022, then tumbled by 119.9% to -$18.1 billion in 2023, then grew by 4.76% to -$17.3 billion in 2024, then rose by 4.28% to -$16.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were -$16.5 billion in Q1 2025, -$17.3 billion in Q1 2024, and -$18.1 billion in Q1 2023.